WOLF CREEK, MT / ACCESSWIRE / August 24, 2022 / Today Solo-Dex announces an exclusive Product Distribution Agreement ("Agreement") for Solo-Dex Fascile® suite of products with CH Trading Group LLC ("CH Trading"), an international import, export and trading company. The Agreement focuses on the MENA regional markets, and extends the availability of Solo-Dex Fascile products beyond the U.S., Europe and Brazil to dozens of countries, including those part of the Gulf Cooperation Council (GCC), the African Union and the Organization of Islamic Cooperation (OIC).
"The Solo-Dex products are particularly well suited to improve patient satisfaction and reduce opioid abuse, because they are fast, simple and reliable - and stay in place for days during at-home recovery. We are confident that the use of Solo-Dex technology will grow rapidly because it is cost-effective and provides a wide margin of safety through full control of the amount, timing and type of medication selected," said Steven Eror, CEO of Solo-Dex. He added, "The CH Group respects MedTech innovation and is aligned with our mission to improve the patient's recovery experience without the use of oral opioid therapy."
Elsayed Zayan, CEO of the CH Group family of companies, which includes CH Trading, remarked, "Our distribution Agreement with Solo-Dex promotes our mission by bringing significant medical innovation to communities, health systems, physicians and their patients."
About CH Trading Group
CH Trading Group LLC ("CH Trading") is part of the CH Group family of companies ( www.chgroupus.com ). CH Group constitutes a diversified conglomerate targeting eight economic "Sectors": healthcare, pharmaceuticals, food, finance, cosmetics, tourism, fashion, media/entertainment. Spanning a variety of multi-national products, services and solutions, its world mission involves connecting, developing and promoting, from Local to Global™ and throughout the world, all aspects of a wholesome, healthy and productive lifestyle.
CH Trading focuses on international import/export and trade, prioritizing the countries of the Organization of Islamic Cooperation (OIC), as well as the Middle East and North Africa (MENA) and Gulf Cooperation Council (GCC) Regions. It has responded to worldwide demands for identifying and securing supply chains by introducing innovative products, including from the US, and developing a robust distribution network for goods.
About Solo-Dex, Inc.
Solo-Dex is a private MedTech company focused on delivering precise, sustainable and regulatable control of patient pain with its Fascile® suite of continuous peripheral nerve block catheters. Solo-Dex proprietary catheters lead the industry and are designed for single operator control of ultrasound visualization, nerve catheter and pain medication. Solo-Dex technology reduces complexity and unlocks the potential of increased patient satisfaction through at-home recovery. Solo-Dex's goal is to become the standard of care for acute pain management before, during and for days after surgery.
Steve Eror, CEO
SOURCE: Solo-Dex, Inc.